Point mutation in CD19 facilitates immune escape of B cell lymphoma from CAR-T cell therapy

BACKGROUND: Tumor relapse due to mutation in CD19 can hinder the efficacy of chimeric antigen receptor (CAR)-T cell therapy. Herein, we focused on lymphoma patients whose B cells exhibited a point mutation in CD19 of B cells after CAR-T cell infusion. METHODS: The CAR-T and CD19(+) B cells from peri...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Zhen, Chen, Xinfeng, Tian, Yonggui, Li, Feng, Zhao, Xuan, Liu, Jinyan, Yao, Chang, Zhang, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539592/
https://www.ncbi.nlm.nih.gov/pubmed/33023981
http://dx.doi.org/10.1136/jitc-2020-001150

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539592/
https://www.ncbi.nlm.nih.gov/pubmed/33023981
http://dx.doi.org/10.1136/jitc-2020-001150

Ejemplares similares